Bupropion was not more effective than placebo in improving sexual desire/energy in female cancer survivors who had completed treatment for breast and gynecologic cancers.
Despite preliminary supporting evidence that the dopaminergic agent bupropion might improve sexual desire for female cancer survivors, the NRG Oncology CC004 clinical trial determined that bupropion did not improve outcomes when compared to a placebo.